INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,372,354 | +1531.6% | 289,771 | +873.3% | 0.00% | – |
| Q2 2023 | $329,278 | -87.5% | 29,772 | -84.8% | 0.00% | – |
| Q1 2023 | $2,625,000 | +53384.1% | 195,468 | -50.7% | 0.00% | -100.0% |
| Q4 2022 | $4,908 | -99.8% | 396,803 | +128.2% | 0.00% | – |
| Q3 2022 | $2,425,000 | -46.0% | 173,851 | -46.5% | 0.00% | -100.0% |
| Q2 2022 | $4,488,000 | -9.7% | 324,980 | +6.4% | 0.00% | 0.0% |
| Q1 2022 | $4,970,000 | +66.3% | 305,441 | +66.5% | 0.00% | – |
| Q4 2021 | $2,989,000 | +1.5% | 183,486 | -7.5% | 0.00% | – |
| Q3 2021 | $2,944,000 | -86.7% | 198,312 | -82.1% | 0.00% | -100.0% |
| Q2 2021 | $22,144,000 | -0.6% | 1,108,855 | +14.9% | 0.00% | 0.0% |
| Q1 2021 | $22,281,000 | -31.6% | 965,351 | -26.8% | 0.00% | -40.0% |
| Q4 2020 | $32,560,000 | -37.9% | 1,318,215 | +5.1% | 0.01% | -44.4% |
| Q3 2020 | $52,416,000 | -30.7% | 1,254,550 | -20.5% | 0.01% | -40.0% |
| Q2 2020 | $75,631,000 | -18.2% | 1,578,602 | +7.4% | 0.02% | -31.8% |
| Q1 2020 | $92,510,000 | -51.0% | 1,469,343 | -3.6% | 0.02% | -37.1% |
| Q4 2019 | $188,905,000 | +94.4% | 1,524,413 | +4.1% | 0.04% | +84.2% |
| Q3 2019 | $97,182,000 | -4.8% | 1,464,478 | +13.9% | 0.02% | -5.0% |
| Q2 2019 | $102,097,000 | +21.9% | 1,285,692 | +71.7% | 0.02% | +17.6% |
| Q1 2019 | $83,781,000 | -33.2% | 748,985 | -39.8% | 0.02% | -41.4% |
| Q4 2018 | $125,380,000 | -17.1% | 1,243,971 | +3.9% | 0.03% | 0.0% |
| Q3 2018 | $151,258,000 | +41.7% | 1,197,042 | -5.9% | 0.03% | +31.8% |
| Q2 2018 | $106,757,000 | +5.9% | 1,272,281 | -22.4% | 0.02% | 0.0% |
| Q1 2018 | $100,842,000 | -10.7% | 1,639,175 | -15.2% | 0.02% | -8.3% |
| Q4 2017 | $112,911,000 | +119.7% | 1,932,734 | +116.8% | 0.02% | +118.2% |
| Q3 2017 | $51,382,000 | -15.7% | 891,573 | +77.1% | 0.01% | -21.4% |
| Q2 2017 | $60,963,000 | -37.8% | 503,538 | -41.9% | 0.01% | -36.4% |
| Q1 2017 | $98,031,000 | +6.5% | 866,765 | +2.3% | 0.02% | 0.0% |
| Q4 2016 | $92,029,000 | -33.0% | 847,013 | +1.6% | 0.02% | -35.3% |
| Q3 2016 | $137,277,000 | +16.0% | 834,053 | +0.6% | 0.03% | +13.3% |
| Q2 2016 | $118,345,000 | +180.8% | 829,438 | +152.8% | 0.03% | +172.7% |
| Q1 2016 | $42,153,000 | -10.7% | 328,114 | +3.8% | 0.01% | -8.3% |
| Q4 2015 | $47,194,000 | -6.8% | 315,997 | +3.5% | 0.01% | -14.3% |
| Q3 2015 | $50,659,000 | -28.0% | 305,428 | +4.7% | 0.01% | -17.6% |
| Q2 2015 | $70,405,000 | -9.1% | 291,674 | +6.2% | 0.02% | -5.6% |
| Q1 2015 | $77,433,000 | +805.5% | 274,566 | +400.9% | 0.02% | +800.0% |
| Q4 2014 | $8,551,000 | +132.0% | 54,817 | +252.0% | 0.00% | +100.0% |
| Q3 2014 | $3,685,000 | +54.8% | 15,572 | +54.8% | 0.00% | 0.0% |
| Q2 2014 | $2,381,000 | -85.2% | 10,057 | -79.4% | 0.00% | -75.0% |
| Q1 2014 | $16,107,000 | +238.2% | 48,837 | -54.0% | 0.00% | +100.0% |
| Q2 2013 | $4,763,000 | – | 106,209 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |